Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
This study is a multicenter, single arm, prospective study aimed at evaluating the efficacy and safety of adebelimab combined with short course radiotherapy (5 \* 5Gy) and chemotherapy as preoperative neoadjuvant therapy for locally advanced rectal cancer patients. In the study, all subjects who met the inclusion criteria will receive a combination of adebelimab, short course radiotherapy (5 \* 5Gy), and CAPOX chemotherapy as neoadjuvant therapy according to the study plan. TME surgery will be performed 2-3 weeks after the last dose of neoadjuvant therapy. If the surgery cannot be performed within the time window specified in the protocol (such as delayed adverse reactions, etc.), the researcher will consider the actual clinical situation of the subjects comprehensively.
Rectal Cancer|Advanced Stage Colorectal Cancer|Radiotherapy
DRUG: Adebrelimab Injection combined with radiotherapy and chemotherapy
Pathological complete remission rate (pCR), Pathological complete remission rate (pCR), From enrollment to the end of surgery,assessed up to 6 months
Objective response rate (ORR), Objective response rate (ORR), The evaluation time from enrollment to the first efficacy evaluation is up to 3 months|Major Pathological Response Rate (MPR), Major Pathological Response Rate (MPR), From enrollment to the end of surgery,assessed up to 6 months|R0 resection rate, R0 resection rate, From enrollment to the end of surgery,assessed up to 6 months|Adverse reaction incidence rate, Adverse reaction incidence rate, From enrollment to 90 days after the last medication
This study is a multicenter, single arm, prospective study aimed at evaluating the efficacy and safety of adebelimab combined with short course radiotherapy (5 \* 5Gy) and chemotherapy as preoperative neoadjuvant therapy for locally advanced rectal cancer patients. In the study, all subjects who met the inclusion criteria will receive a combination of adebelimab, short course radiotherapy (5 \* 5Gy), and CAPOX chemotherapy as neoadjuvant therapy according to the study plan. TME surgery will be performed 2-3 weeks after the last dose of neoadjuvant therapy. If the surgery cannot be performed within the time window specified in the protocol (such as delayed adverse reactions, etc.), the researcher will consider the actual clinical situation of the subjects comprehensively.